These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 35906608)
21. Natural history of spinal muscular atrophy in children: an analysis of 117 cases. Yang YY; Yuan P; Li M; Jiang L; Hong SQ Zhongguo Dang Dai Er Ke Za Zhi; 2021 Oct; 23(10):1038-1043. PubMed ID: 34719420 [TBL] [Abstract][Full Text] [Related]
22. Functional and surgical treatments in patients with spinal muscular atrophy (SMA). Boulay C; Peltier E; Jouve JL; Pesenti S Arch Pediatr; 2020 Dec; 27(7S):7S35-7S39. PubMed ID: 33357596 [TBL] [Abstract][Full Text] [Related]
23. Observation of the natural course of type 3 spinal muscular atrophy: data from the polish registry of spinal muscular atrophy. Lusakowska A; Jedrzejowska M; Kaminska A; Janiszewska K; Grochowski P; Zimowski J; Sierdzinski J; Kostera-Pruszczyk A Orphanet J Rare Dis; 2021 Mar; 16(1):150. PubMed ID: 33761963 [TBL] [Abstract][Full Text] [Related]
24. Risdiplam in non-sitter patients aged 16 years and older with 5q spinal muscular atrophy. Ñungo Garzón NC; Pitarch Castellano I; Sevilla T; Vázquez-Costa JF Muscle Nerve; 2023 May; 67(5):407-411. PubMed ID: 36815750 [TBL] [Abstract][Full Text] [Related]
25. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1. Dabbous O; Maru B; Jansen JP; Lorenzi M; Cloutier M; Guérin A; Pivneva I; Wu EQ; Arjunji R; Feltner D; Sproule DM Adv Ther; 2019 May; 36(5):1164-1176. PubMed ID: 30879249 [TBL] [Abstract][Full Text] [Related]
26. Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy. Sergott RC; Amorelli GM; Baranello G; Barreau E; Beres S; Kane S; Mercuri E; Orazi L; SantaMaria M; Tremolada G; Santarsiero D; Waskowska A; Yashiro S; Denk N; Fürst-Recktenwald S; Gerber M; Gorni K; Jaber B; Jacobsen B; Mueller L; Nave S; Scalco RS; Marzoli SB; Ann Clin Transl Neurol; 2021 Jan; 8(1):54-65. PubMed ID: 33231373 [TBL] [Abstract][Full Text] [Related]
27. Observational study of spinal muscular atrophy type I and implications for clinical trials. Finkel RS; McDermott MP; Kaufmann P; Darras BT; Chung WK; Sproule DM; Kang PB; Foley AR; Yang ML; Martens WB; Oskoui M; Glanzman AM; Flickinger J; Montes J; Dunaway S; O'Hagen J; Quigley J; Riley S; Benton M; Ryan PA; Montgomery M; Marra J; Gooch C; De Vivo DC Neurology; 2014 Aug; 83(9):810-7. PubMed ID: 25080519 [TBL] [Abstract][Full Text] [Related]
28. Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years. Vill K; Schwartz O; Blaschek A; Gläser D; Nennstiel U; Wirth B; Burggraf S; Röschinger W; Becker M; Czibere L; Durner J; Eggermann K; Olgemöller B; Harms E; Schara U; Kölbel H; Müller-Felber W Orphanet J Rare Dis; 2021 Mar; 16(1):153. PubMed ID: 33789695 [TBL] [Abstract][Full Text] [Related]
29. Clinical features of spinal muscular atrophy (SMA) type 3 (Kugelberg-Welander disease). Salort-Campana E; Quijano-Roy S Arch Pediatr; 2020 Dec; 27(7S):7S23-7S28. PubMed ID: 33357593 [TBL] [Abstract][Full Text] [Related]
30. Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study. Audic F; de la Banda MGG; Bernoux D; Ramirez-Garcia P; Durigneux J; Barnerias C; Isapof A; Cuisset JM; Cances C; Richelme C; Vuillerot C; Laugel V; Ropars J; Altuzarra C; Espil-Taris C; Walther-Louvier U; Sabouraud P; Chouchane M; Vanhulle C; Trommsdorff V; Pervillé A; Testard H; Lagrue E; Sarret C; Avice AL; Beze-Beyrie P; Pauly V; Quijano-Roy S; Chabrol B; Desguerre I Orphanet J Rare Dis; 2020 Jun; 15(1):148. PubMed ID: 32532349 [TBL] [Abstract][Full Text] [Related]
31. Drug treatment for spinal muscular atrophy type I. Wadman RI; Bosboom WM; van den Berg LH; Wokke JH; Iannaccone ST; Vrancken AF Cochrane Database Syst Rev; 2011 Dec; (12):CD006281. PubMed ID: 22161399 [TBL] [Abstract][Full Text] [Related]
32. Drug treatment for spinal muscular atrophy type I. Wadman RI; Bosboom WM; van der Pol WL; van den Berg LH; Wokke JH; Iannaccone ST; Vrancken AF Cochrane Database Syst Rev; 2012 Apr; (4):CD006281. PubMed ID: 22513939 [TBL] [Abstract][Full Text] [Related]
33. Population-based analysis of survival in spinal muscular atrophy. Wijngaarde CA; Stam M; Otto LAM; van Eijk RPA; Cuppen I; Veldhoen ES; van den Berg LH; Wadman RI; van der Pol WL Neurology; 2020 Apr; 94(15):e1634-e1644. PubMed ID: 32217777 [TBL] [Abstract][Full Text] [Related]
34. Respiratory management of spinal muscular atrophy type 1 patients treated with Nusinersen. Menard J; Seferian AM; Fleurence E; Barzic A; Binoche A; Labouret G; Coutier L; Vuillerot C; Bieleu BM; Gomez Garcia de la Banda M; Corvol H; Servais L; Taytard J Pediatr Pulmonol; 2022 Jun; 57(6):1505-1512. PubMed ID: 35307979 [TBL] [Abstract][Full Text] [Related]
35. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis. Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland. Tscherter A; Rüsch CT; Baumann D; Enzmann C; Hasselmann O; Jacquier D; Jung HH; Kruijshaar ME; Kuehni CE; Neuwirth C; Stettner GM; Klein A; Neuromuscul Disord; 2022 May; 32(5):399-409. PubMed ID: 35337708 [TBL] [Abstract][Full Text] [Related]